查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830987

呼吸道感染治疗市场

Respiratory Tract Infection Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

呼吸道感染治疗市场预计将从 2024 年的 440.9 亿美元成长到 2031 年的 691.3 亿美元，预计 2025 年至 2031 年期间的复合年增长率为 5.93%。呼吸道感染 (RTI) 会影响鼻窦、喉咙、呼吸道或肺部。全球呼吸道感染治疗市场报告强调了推动市场成长的主要因素，并概述了主要参与者的进展。成长动力包括全球呼吸道感染发病率的上升、对 RTI 及其治疗的认识的提高以及越来越多的针对 RTI 疗法的临床试验。然而，对呼吸疗法的研究有限以及与 RTI 药物相关的副作用对市场扩张构成了挑战。此外，预计抗病毒治疗的出现将在不久的将来为全球呼吸道感染治疗市场带来新的趋势。

成长动力与限制因素：老年人呼吸系统疾病诊断需求不断增长随着全球老年人口的增长，预计未来几年呼吸系统疾病诊断需求将持续成长。例如，2021年11月发表在《英国药理学杂誌》上的一项研究指出，英国每年约有1%的人口被诊断出患有社区获得性肺炎 (CAP)，其中约70%发生在65岁以上的人群中，该人群的30天死亡率约为20%。因此，人口老化和CAP等疾病发病率的上升可能会推动呼吸系统疾病治疗的需求，从而促进整体市场成长。

该领域的持续研发催生了各种诊断测试和程序，预计将在未来几年对市场成长产生积极影响。创新诊断技术可望在预测期内为市场扩张带来巨大机会。然而，呼吸道感染药物相关的研究不足和不良反应可能会限制全球呼吸道感染治疗市场的成长。

策略洞察市场细分与范围：透过研究以下细分市场对全球呼吸道感染治疗市场进行分析：药物类型、疾病适应症、给药途径、年龄层和配销通路。市场依药物分为抗生素、非类固醇抗发炎药、止咳药、鼻减充血剂等。依疾病适应症分为上呼吸道感染和下呼吸道感染。给药途径分为口服和非注射。年龄组细分包括儿科和成人类别。最后，分销管道分为医院药房、网路药房和零售药房。

細項分析：就药物类型而言，抗生素细分市场在2023年占据了全球呼吸道感染治疗市场的最大份额，预计在2023年至2031年期间将呈现最高的复合年增长率。呼吸道感染（RTI）包括支气管炎、肺炎和鼻窦炎等各种疾病，通常由细菌病原体引起。抗生素能够有效靶向并消除这些有害细菌，减轻炎症，并促进患者更快康復。常用的呼吸道感染处方抗生素包括青霉素、头孢菌素、大环内酯类、氟喹诺酮类和四环素类，每种抗生素的作用机转和针对的细菌标靶各不相同。

就疾病适应症而言，下呼吸道感染细分市场在2023年占据了更大的市场份额，预计2023年至2031年期间的复合年增长率将更高。下呼吸道感染 (LRTI) 会影响肺部和支气管，通常由细菌、病毒或真菌病原体引起。肺炎、支气管炎和细支气管炎等疾病的症状包括咳嗽咳痰、胸部不适、呼吸急促和发烧，均属于 LRTI 范畴。肺炎是 LRTI 的一种严重形式，涉及肺组织发炎和感染，导致肺实变和气体交换受损。

按给药途径划分，口服药物在全球呼吸道感染治疗市场中占据主导地位，预计在2023年至2031年期间将实现更高的复合年增长率。口服抗生素，例如阿莫西林、阿奇霉素和强力霉素，通常用于治疗导致呼吸道感染的细菌性病原体。此外，口服皮质类固醇可用于缓解重症气喘或慢性阻塞性肺病 (COPD) 急性发作期的发炎。奥司他韦等口服抗病毒药物也用于治疗流感等病毒性呼吸道感染。口服途径具有给药方便、患者依从性高及药物全身分布等优点。

从年龄层来看，2023年成人呼吸道感染治疗市场在全球呼吸道感染治疗市场中占据较大份额，而儿科市场预计在2023年至2031年间将呈现更高的复合年增长率。人们越来越意识到早期诊断和治疗儿童呼吸道感染的重要性，以及呼吸设备的进步，这些因素正在推动新的、更有效的治疗方案的发展。此外，对预防性医疗保健的日益重视也促进了儿科市场的成长。

在分销管道方面，预计医院药房将在2023年至2031年期间占据显着的市场份额。医院药局是医疗保健系统的重要组成部分，尤其在治疗需要静脉或肌肉注射药物的急性和严重呼吸道感染方面发挥重要作用。这些药局负责购买、储存和调配抗生素、抗病毒药物、皮质类固醇和其他呼吸道感染治疗药物，确保这些药物安全及时地送达医院内的住院和门诊病患。

呼吸道感染治疗市场报告范围区域分析：人们越来越意识到早期诊断和治疗呼吸道感染的重要性，这可能会推动未来几年全球呼吸道感染治疗市场的成长。市场细分为北美、欧洲、亚太、中东和非洲以及南美和中美。 2023 年，北美占据全球呼吸道感染治疗市场的最大份额，由于该地区呼吸道感染的高发病率，该地区经历了显着增长。造成呼吸道感染发生率高的因素包括空气污染、吸烟和拥挤的生活条件。呼吸道感染盛行率的上升、医疗保健意识的提高以及政府的有利倡议正在推动全球呼吸道感染治疗市场的成长。

竞争格局与关键参与者：全球呼吸道感染治疗市场的预测可以帮助利害关係人规划其成长策略。全球呼吸道感染治疗市场报告中介绍的主要参与者包括雅培实验室、阿斯特捷利康公司、Alembic Pharmaceuticals Ltd.、勃林格殷格翰国际有限公司、葛兰素史克公司、梯瓦製药工业有限公司、诺华公司、罗氏公司、赛诺菲公司、默克公司和西普拉。这些公司采用各种策略（有机和无机）来满足不断增长的消费者需求，并扩大其专业产品组合中的产品供应。这些公司采用的主要策略包括推出新技术、开发现有产品和扩展地域范围。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：呼吸道感染治疗市场格局

  • 概述
  • PEST分析

第五章：呼吸道感染治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：呼吸道感染治疗市场-全球市场分析

  • 呼吸道感染治疗－全球市场概览
  • 呼吸道感染治疗－全球市场及2031年预测

第七章：呼吸道感染治疗市场－收入分析－依药物分类，2021-2031

  • 概述
  • 抗生素
  • 非类固醇抗发炎药（NSAIDS）
  • 止咳药
  • 鼻减充血剂
  • 其他的

第八章：呼吸道感染治疗市场-收入分析-按疾病适应症，2021-2031

  • 概述
  • 上呼吸道感染
  • 下呼吸道感染

第九章：呼吸道感染治疗市场-收入分析-按配销通路，2021-2031

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：呼吸道感染治疗市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第十三章：呼吸道感染治疗市场－主要公司简介

  • Abbott
  • AstraZeneca
  • Merck and Co
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Cipla
  • Novartis AG
  • F. Hoffmann La Roche Ltd
  • Sanofi

第 14 章：附录

简介目录
Product Code: TIPRE00003835

The respiratory tract infection treatment market is projected to grow from US$ 44.09 billion in 2024 to US$ 69.13 billion by 2031, with an expected CAGR of 5.93% during the period from 2025 to 2031.Respiratory tract infections (RTIs) affect the sinuses, throat, airways, or lungs. The global market report for respiratory tract infection treatment highlights the main factors propelling market growth and outlines the advancements made by key players. The growth drivers include the increasing global incidence of respiratory infections, heightened awareness regarding RTIs and their treatments, and a growing number of clinical trials focused on RTI therapies. However, limited research on respiratory therapeutics and the side effects associated with RTI medications pose challenges to market expansion. Additionally, the emergence of antiviral treatments is anticipated to introduce new trends in the global respiratory tract infection treatment market in the near future.

Growth Drivers and Restraints:Increasing Demand for Respiratory Disease Diagnosis in the Elderly

With the global elderly population on the rise, the demand for diagnosing respiratory diseases is expected to grow in the upcoming years. For example, a study published in the British Journal of Pharmacology in November 2021 noted that approximately 1% of the UK population is diagnosed with community-acquired pneumonia (CAP) each year, with around 70% of these cases occurring in individuals over 65 years old, and a 30-day mortality rate of about 20% in this demographic. Therefore, the aging population and the increasing incidence of conditions like CAP are likely to drive demand for respiratory disease treatments, thereby enhancing overall market growth.

Ongoing research and development in this area have led to the creation of various diagnostic tests and procedures that are expected to positively influence market growth in the coming years. Innovative diagnostic techniques are likely to provide significant opportunities for market expansion during the forecast period. However, the lack of research studies and adverse reactions associated with respiratory infection medications may limit the growth of the global respiratory tract infection treatment market.

Strategic Insights

Market Segmentation and Scope:The analysis of the global respiratory tract infection treatment market has been conducted by examining the following segments: drug type, disease indication, route of administration, age group, and distribution channel. The market is categorized by drugs into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. By disease indication, it is divided into upper respiratory tract infections and lower respiratory tract infections. The route of administration is classified into oral and parenteral. The age group segmentation includes pediatric and adult categories. Lastly, the distribution channels are segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Segment Analysis:In terms of drug type, the antibiotics segment accounted for the largest share of the global respiratory tract infection treatment market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031. RTIs include various conditions such as bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens. Antibiotics are effective in targeting and eliminating these harmful bacteria, reducing inflammation, and facilitating quicker recovery. Commonly prescribed antibiotics for RTIs include penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, each with distinct mechanisms of action and bacterial targets.

Regarding disease indication, the lower respiratory tract infection segment held a larger market share in 2023 and is projected to experience a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) affect the lungs and bronchial tubes and are typically caused by bacterial, viral, or fungal pathogens. Conditions such as pneumonia, bronchitis, and bronchiolitis, which present symptoms like productive cough, chest discomfort, shortness of breath, and fever, fall under the LRTI category. Pneumonia, a severe form of LRTI, involves inflammation and infection of lung tissue, leading to pulmonary consolidation and impaired gas exchange.

By route of administration, the oral segment dominated the global respiratory tract infection treatment market and is expected to register a higher CAGR during 2023 to 2031. Oral antibiotics such as amoxicillin, azithromycin, and doxycycline are commonly prescribed to treat bacterial pathogens responsible for RTIs. Additionally, oral corticosteroids may be used to alleviate inflammation in severe asthma or chronic obstructive pulmonary disease (COPD) exacerbations. Oral antiviral medications like oseltamivir are also utilized for treating viral respiratory infections such as influenza. The oral route offers advantages such as ease of administration, patient compliance, and systemic drug distribution.

In terms of age group, the adult segment held a larger share of the global respiratory tract infection treatment market in 2023, while the pediatric segment is expected to show a higher CAGR from 2023 to 2031. Factors such as increased awareness of the importance of early diagnosis and treatment of respiratory infections in children, along with advancements in respiratory devices, are leading to the development of new and more effective treatment options. Furthermore, the growing emphasis on preventive healthcare is contributing to the market growth for the pediatric segment.

Regarding distribution channels, the hospital pharmacies segment is expected to capture a significant market share from 2023 to 2031. Hospital pharmacies are crucial components of healthcare systems, particularly in managing acute and severe respiratory tract infections that require intravenous or intramuscular medication administration. These pharmacies are responsible for sourcing, storing, and dispensing antibiotics, antivirals, corticosteroids, and other treatments for respiratory infections, ensuring their safe and timely delivery to both inpatient and outpatient settings within hospitals.

Scope of the Respiratory Tract Infection Treatment Market Report

Regional Analysis:Growing awareness among the population regarding the significance of early diagnosis and treatment of respiratory infections is likely to drive the global respiratory tract infection treatment market growth in the coming years. The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America. North America held the largest share of the global respiratory tract infection treatment market in 2023, experiencing significant growth due to the high prevalence of respiratory tract infections in the region. Contributing factors include air pollution, smoking, and crowded living conditions, which lead to a high incidence of respiratory infections. The increase in respiratory infection prevalence, heightened healthcare awareness, and favorable government initiatives are propelling the growth of the global respiratory tract infection treatment market.

Competitive Landscape and Key Players:The forecast for the global respiratory tract infection treatment market can assist stakeholders in planning their growth strategies. Key players profiled in the global respiratory tract infection treatment market report include Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co., and Cipla. These companies employ various strategies (both organic and inorganic) to meet the growing consumer demand and expand their product offerings in specialized portfolios. Major strategies adopted by these companies include launching new technologies, developing existing products, and expanding geographically.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Respiratory Tract Infection Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Respiratory Tract Infection Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Respiratory Tract Infection Treatment Market - Global Market Analysis

  • 6.1 Respiratory Tract Infection Treatment - Global Market Overview
  • 6.2 Respiratory Tract Infection Treatment - Global Market and Forecast to 2031

7. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Drug, 2021-2031

  • 7.1 Overview
  • 7.2 Antibiotics
  • 7.3 Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
  • 7.4 Cough Suppressant
  • 7.5 Nasal Decongestant
  • 7.6 Others

8. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Upper Respiratory Tract Infection
  • 8.3 Lower Respiratory Tract Infection

9. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10. Respiratory Tract Infection Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Respiratory Tract Infection Treatment Market Overview
    • 10.1.2 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Drug
    • 10.1.4 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Respiratory Tract Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Respiratory Tract Infection Treatment Market
        • 10.1.6.1.1 United States Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.1.2 United States Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Respiratory Tract Infection Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Respiratory Tract Infection Treatment Market
        • 10.1.6.2.1 Canada Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.2.2 Canada Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Respiratory Tract Infection Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Respiratory Tract Infection Treatment Market
        • 10.1.6.3.1 Mexico Respiratory Tract Infection Treatment Market, by Drug
        • 10.1.6.3.2 Mexico Respiratory Tract Infection Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Respiratory Tract Infection Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Respiratory Tract Infection Treatment Market - Key Company Profiles

  • 13.1 Abbott
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AstraZeneca
  • 13.3 Merck and Co
  • 13.4 Boehringer Ingelheim International GmbH
  • 13.5 GlaxoSmithKline plc
  • 13.6 Teva Pharmaceutical Industries Ltd
  • 13.7 Cipla
  • 13.8 Novartis AG
  • 13.9 F. Hoffmann La Roche Ltd
  • 13.10 Sanofi

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud